Radioimmunotherapy of Cancer

Reflecting the past 20 years of intense research in radioimmunotherapy, this timely reference surveys an expansive breadth of topics on the evolving developments in radiation therapy. Placed in the context of advances in cancer treatment, chapters progress systematically from basic principles and properties of radionuclides to detailed summaries of current cancer therapies. Up to date, clearly organized, and thorough-sure to become a standard in the field! Providing comprehensive treatment on radiolabeled antibody therapy, Radioimmunotherapy of Cancer ·reviews dosimetric principles and clinical dosimetry of radioimmunotherapy in the targeting and delivery of radiation ·describes tumor architectures and outlines novel constructs for radionuclide delivery ·analyzes a variety of improved targeting approaches, including pretargeting contextual analysis of extracorporeal techniques in radioimmunotherapy ·details studies from the radiotherapy of lymphoma, solid tumors, and ovarian cancer and the targeted radiotherapy of neuroblastoma and squamous head and neck cancer ·and much more! With contributions from nearly 50 international experts and containing over 1300 literature references, drawings, photographs, tables, and equations, Radioimmunotherapy of Cancer is an invaluable and indispensable reference for physicians in nuclear medicine and medical physicists; oncologists, radiologists, radiochemists, and radiopharmacists; immunologists, pulmonologists, and cancer researchers; pharmacologists and drug delivery pharmaceutical chemists; and upper-level undergraduate, graduate, and medical school students in these disciplines. Cover......Page 1 Contents......Page 8 Contributors......Page 10 Dosimetris: Principles of Targeted Radiotherapy......Page 14 Radianuclide Dosimetry Eand ......Page 34 Metallic Radionuclides for Radioimmunotherapy......Page 70 Radiohalogens for Radioimmunotherapy......Page 94 Tumor Architecture and Targeted Delivery......Page 120 Antibodies and Novel Constructs for Tumor Targeting......Page 150 Pretargeted Radioimmunotherapy of Cancer......Page 182 Evolution of a Pretarget Radioimmunotherapeutic Regimen......Page 208 Extracorporeal Techniques in Radioimmunotherapy......Page 236 Radioimmunotherapiny in the Treatment of Non-Hodgkin’sLymphoma......Page 258 Radioimmunotherapy of solid Tumors......Page 278 Intraperitoneal Radioimmunotherapy of f Ovarian Cancer......Page 320 Targeted Radiotherapy in the Treatment of Osteosarcoma......Page 336 Targeted Radiotherapy of Neuroblastoma......Page 352 Targeted Radiotherapy of Squamous Head and Neck Cancer......Page 374 Index......Page 402 Annotation Surveys the breadth of evolving developments in radiation therapy. Placed in the context of advances in cancer treatment, chapters progress from basic principles and properties of radionuclides to detailed summaries of current cancer therapies. Reviews dosimetric principles and clinical dosimetry of radioimmunotherapy in the targeting and delivery of radiation, describes tumor architectures and outlines novel constructs for radionuclide delivery, analyzes improved targeting approaches and extracorporeal techniques, and details studies of radiotherapy of lymphoma, solid tumors, and ovarian cancer. Abrams is CEO and Fritzberg is chief scientist of NeoRx Corporation Annotation c. Book News, Inc., Portland, OR (booknews.com) "Radioimmunotherapy of Cancer reviews dosimetric principles and clinical dosimetry of radioimmunotherapy in the targeting and delivery of radiation ... describes tumor architectures and outlines novel constructs for radionuclide delivery ... analyzes a variety of improved targeting approaches, including pretargeting contextual analysis of extracorporeal techniques in radioimmunotherapy ... details studies from the radiotherapy of lymphoma, solid tumors, and ovarian cancer and the targeted radiotherapy of neuroblastoma and squamous head and neck cancer ... and much more."--BOOK JACKET Covering key topics of radiolabelled antibodies for targeted radiotherapy (RIT) of cancer, this study includes chapters on: radionuclide properties and their selection for RIT; in vivo dosimetry; and new approaches to improving targeting and treatment of tumours and lymphomas with RIT For disseminated or diffuse malignant disease a systemic approach to treatment is required.